NCT05546515View on ClinicalTrials.gov

Suvorexant for Opioid/Stimulant Co-use

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

December 1, 2022

Primary Completion Date

November 30, 2024

Study Completion Date

November 30, 2024

Conditions
Opioid Use DisorderStimulant Use Disorder
Interventions
DRUG

Suvorexant (dual orexin receptor antagonist)

Participants will be prescribed up to 30 days of SUVO.

DRUG

Placebo

Participants will be prescribed up to 30 days of placebo medication.

Trial Locations (1)

21224

Behavioral Pharmacology Research Unit at the Johns Hopkins Bayview Medical Center, Baltimore

All Listed Sponsors
lead

Johns Hopkins University

OTHER